drugset / Trial / NCT05294328

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

NCT05294328

Phase 2 Completed 68 enrolled LENZ Therapeutics, Inc
RandomizedCrossoverTriple-blindTreatment

Summary

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

Timeline

Start
2022-05-05
Primary completion
2022-08-22
Completion
2022-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aceclidine Small molecule Other
Subject Brimonidine Small molecule Other

Indications